Vaccination with a regulatory t-cell inducing vaccine formulation containing apob100 peptides, reduces atherosclerosis in mice.

Benne, Naomi; Duijn, Janine van; Vigario, Fernando Lozano; Leboux, Romain; Veelen, Peter van; Jiskoot, Wim; Kuiper, J.; Slütter, Bram

doi:10.1016/j.atherosclerosis.2019.06.289

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, the stable lipid-polymeric nanoparticle can provide the conjugated antigen with a particulate nature, [36][37][38] leading to an improved recognition and capture by antigen presenting cells, as the immune system prefers to recognize particulate antigens rather than soluble protein antigens. 23,39,40 Second, the antigens (conjugated to nanoparticle surface) and molecular adjuvants (encapsulated within nanoparticles) could be codelivered to the same antigen presenting cells. The co-localization of antigens and adjuvants in the same antigen presenting cells could augment antigen presentation and T help cell activation, 41 thus facilitating B cell activation and maturation.…”

Section: Discussionmentioning

confidence: 99%

Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine

Zhao¹,

Hu²,

Harmon

et al. 2019

Mol. Pharmaceutics

View full text Add to dashboard Cite

Adjuvants are a critical component for vaccines, especially for a poorly immunogenic antigen, such as nicotine. However, the impact of adjuvant release rate from a vaccine formulation on its immunogenicity has not been well illustrated. In this study, we fabricated a series of hybridnanoparticle-based nicotine vaccines to study the impact of adjuvant release rate on their immunological efficacy. It was found that the nanovaccine with a medium or slow adjuvant release rate induced a significantly higher anti-nicotine antibody titer than that with a fast release rate. Furthermore, the medium and slow adjuvant release rates resulted in a significantly lower brain nicotine concentration than the fast release rate after nicotine challenge. All findings suggest that adjuvant release rate affects the immunological efficacy of nanoparticle-based nicotine vaccines, providing a potential strategy to rationally designing vaccine formulations against psychoactive drugs or even other antigens. The hybrid-nanoparticle-based nicotine vaccine with an optimized adjuvant release rate can be a promising next-generation immunotherapeutic candidate against nicotine.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine

Zhao¹,

Hu²,

Harmon

et al. 2019

Mol. Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Polymers also offer flexible control over their degradation profile and the release rate of vaccine cargos such as antigens or adjuvants. 101,102 Moreover, polymers offer the potential to co-deliver antigens and immunostimulants, which can increase potency and minimize dose, as well as the associated off-target effects.…”

Section: Polymeric Biomaterialsmentioning

confidence: 99%

“…Using techniques including sonication or homogenization, PLGA polymers can be formulated into nanoparticles (NPs) or microparticles (MPs), 120 and these diverse size scales influence vaccine trafficking, uptake by APCs, and the subsequent immune response. 101,102,111,121 For example, MPs (> 500 nm) tend to accumulate at the injection sites and prolong the stimulation and antigen presentation by APCs. This antigen depot effect has been shown to strongly elicit antibody-and cell-mediated responses against Toxoplasma gondii infection.…”

Section: Polymeric Biomaterialsmentioning

confidence: 99%

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Yenkoidiok-Douti

Jewell

2020

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Despite the success of vaccines in preventing many infectious diseases, effective vaccines against pathogens with ongoing challenges -such as HIV, malaria, and tuberculosis -remain unavailable. The emergence of new pathogen variants, the continued prevalence of existing pathogens, and the resurgence of yet other infectious agents motivate the need for new, interdisciplinary approaches to direct immune responses. Many current and candidate vaccines, for example, are poorly immunogenic, provide only transient protection, or create risks of regaining pathogenicity in certain immune-compromised conditions. Recent advances in biomaterials research are creating new potential to overcome these challenges through improved formulation, delivery, and control of immune signaling. At the same time, many of these materials systems -such as polymers, lipids, and self-assembly technologies -may achieve this goal while maintaining favorable safety profiles. This review highlights ways in which biomaterials can advance existing vaccines to safer, more efficacious technologies, and support new vaccines for pathogens that do not yet have vaccines. Biomaterials that have not yet been applied to vaccines for infectious disease are also discussed, and their potential in this area is highlighted

show abstract

“…[29][30][31] However, conventional MSNs are not ideally suited for neoantigen vaccination, as they have limited loading capacity of peptide antigens due to their relatively small mesopores (0.5-3.0 nm) and have a typical particle size of 200-300 nm, which can compromise their ability to target lymphoid tissues. [31][32][33] In addition, conventional MSNs could cause chronic tissue damage due to slow biodegradation and long-term retention in major organs. 34,35 To address these issues, we have developed small MSNs (~80 nm in diameter) with large 5-10 nm pore size and fast biodegradation rate as a multifunctional nanoplatform for combination immunotherapy (Figure 1).…”

mentioning

confidence: 99%

Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy

et al. 2019

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an effective, noninvasive therapeutic modality against local tumors that are accessible to the source of light. However, it remains challenging to apply PDT for the treatment of disseminated, metastatic cancer. On the other hand, cancer immunotherapy offers a promising approach for generating systemic antitumor immune responses against disseminated cancer. Here we report a multifunctional nanomaterial system for the combination of PDT and personalized cancer immunotherapy and demonstrate their potency against local as well as disseminated tumors. Specifically, we have synthesized uniform and biodegradable mesoporous silica nanoparticles (bMSN) with an average size of ~80 nm and large pore size of 5-10 nm for theranostic positron emission tomography (PET)-guided PDT and neoantigen-based cancer vaccination. Multiple neoantigen peptides, CpG oligodeoxynucleotide adjuvant, and photosensitizer chlorin e6 were coloaded into a bMSN nanoplatform, and PET imaging revealed effective accumulation of bMSN in tumors (up to 9.0% ID/g) after intravenous administration. Subsequent PDT with laser irradiation recruited dendritic cells to PDT-treated tumor sites and elicited neoantigen-specific, tumor-infiltrating cytotoxic T-cell lymphocytes. Using multiple murine models of bilateral tumors, we demonstrate strong antitumor efficacy of PDTimmunotherapy against locally treated tumors as well as distant, untreated tumors. Our findings *

show abstract

Vaccination with a regulatory t-cell inducing vaccine formulation containing apob100 peptides, reduces atherosclerosis in mice.

Cited by 3 publications

References 0 publications

Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine

Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy

Contact Info

Product

Resources

About